Pretreatment with Dual Antiplatelet Therapy in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes undergoing Percutaneous Coronary Intervention
MetadataShow full item record
Background - Although dual antiplatelet therapy is the standard of care in non-ST-segment elevation acute coronary syndromes (NSTEACS), it remains unclear when a second antiplatelet agent should be initiated. We sought to assess the safety and efficacy of pretreatment with clopidogrel in patients with NSTEACS undergoing percutaneous coronary intervention (PCI). Methods - We analyzed baseline clinical and procedural characteristics of 6,817 patients with NSTEACS who underwent PCI from the Melbourne Interventional Group registry from 2005-2012. Patients were included in the pretreatment group if clopidogrel was administered prior to cardiac catheterisation. We assessed 30-day mortality, myocardial infarction (MI) and major adverse cardiovascular events (MACE). The safety endpoint was in-hospital bleeding. Results - Of the 6,817 patients, only 2,951 (43%) received pretreatment with clopidogrel. Patients in the pretreatment group were more likely to present with unstable angina (70.8% vs. 68.2%, p=0.02) and have a history of myocardial infarction (35.6% vs. 23.6%, p < 0.01) but were less likely to have PCI within 24 hours of admission (17.2% vs. 25.2%, p <0.01). There was no difference between the groups in 30-day mortality (0.9% vs. 1.4%, p=0.06), MI (2.0% vs. 2.2%, p=0.52) or MACE (3.7% vs. 4.2%, p=0.25). There was no difference in bleeding complications (1.9% vs. 1.9%, p=0.94). Conclusions - Pretreatment with dual antiplatelet therapy in NSTEACS is not routine clinical practice in Australia. Pretreatment appears safe but is not associated with improved short-term clinical outcomes.
Showing items related by title, author, creator and subject.
Chowdhury, E.; Langham, R.; Ademi, Z.; Owen, A.; Krum, H.; Wing, L.; Nelson, M.; Reid, Christopher (2015)Background - Although dual antiplatelet therapy is the standard of care in non-ST-segment elevation acute coronary syndromes (NSTEACS), it remains unclear when a second antiplatelet agent should be initiated. We sought ...
Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary interventionChan, W.; Ajani, A.; Clark, D.; Stub, D.; Andrianopoulos, N.; Brennan, A.; New, G.; Sebastian, M.; Johnston, R.; Walton, A.; Reid, Christopher; Dart, A.; Duffy, S. (2012)There are few data on the incidence and clinical outcomes of patients with atrial fibrillation (AF) treated in the era of percutaneous coronary intervention (PCI). We analyzed 30-day clinical outcomes in 3,307 consecutive ...
Clopidogrel, Prasugrel or Ticagrelor in Patients with Acute Coronary Syndromes undergoing Percutaneous Coronary Intervention.Yudi, M.; Clark, D.; Farouque, O.; Eccleston, D.; Andrianopoulos, N.; Duffy, S.; Brennan, A.; Lefkovits, J.; Ramchand, J.; Yip, T.; Oqueli, E.; Reid, Christopher; Ajani, A.; Melbourne Interventional Group (2016)Background: Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI). Aim: We sought to describe the trends ...